journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Cancer Institute

journal
https://www.readbyqxmd.com/read/30403799/associations-between-breast-cancer-survivorship-and-adverse-mental-health-outcomes-a-systematic-review
#1
Helena Carreira, Rachael Williams, Martin Müller, Rhea Harewood, Susannah Stanway, Krishnan Bhaskaran
Background: We aimed to systematically review the evidence on adverse mental health outcomes in breast cancer survivors (≥1 year) compared with women with no history of cancer. Methods: Studies were identified by searching MEDLINE, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature, and the Social Sciences Citation Index, and through backward citation tracking. Two researchers selected the studies, extracted data, and assessed the risk of bias...
November 7, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30388268/nsaids-and-colorectal-cancer-phenotypes-what-now
#2
Elizabeth L Barry, Veronika Fedirko, John A Baron
No abstract text is available yet for this article.
November 2, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30388256/association-of-aspirin-and-nonsteroidal-anti-inflammatory-drugs-with-colorectal-cancer-risk-by-molecular-subtypes
#3
Efrat L Amitay, Prudence R Carr, Lina Jansen, Viola Walter, Wilfried Roth, Esther Herpel, Matthias Kloor, Hendrik Bläker, Jenny Chang-Claude, Hermann Brenner, Michael Hoffmeister
Background: Regular use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) for a longer period has been inversely associated with colorectal cancer (CRC) risk. However, CRC is a heterogenic disease, and little is known regarding the associations with molecular pathological subtypes. Methods: Analyses included 2444 cases with a first diagnosis of CRC and 3130 healthy controls from a German population-based case control study. Tumor tissue samples were analyzed for major molecular pathological features: microsatellite instability (MSI), CpG island methylator phenotype, B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation, and Kirsten rat sarcoma viral oncogene homolog gene (KRAS) mutation...
November 2, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30380096/brca1-and-brca2-gene-mutations-and-colorectal-cancer-risk-systematic-review-and-meta-analysis
#4
Mok Oh, Ali McBride, Seongseok Yun, Sandipan Bhattacharjee, Marion Slack, Jennifer R Martin, Joanne Jeter, Ivo Abraham
Background: Investigations of the associations with colorectal cancer have yielded conflicting results. The aim of our study was to synthesize the research on colorectal cancer risks in BRCA mutation carriers by means of a systematic review and quantitatively by means of meta-analyses overall and in subgroups of BRCA mutation carriers. Methods: We searched PubMed/MEDLINE, Embase, Cochrane, Scopus, and ProQuest Dissertation & Theses. Unadjusted odds ratios (ORs) were used to derive pooled estimates of colorectal cancer risk overall and in subgroups defined by mutation type (BRCA1 or BRCA2), cancer type (colorectal or colon cancer), study design (age-sex-adjusted or crude), and ascertainment method (ascertained or inferred genotyping)...
October 31, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30380125/risks-of-colorectal-cancer-and-cancer-related-mortality-in-familial-colorectal-cancer-type-x-and-lynch-syndrome-families
#5
Yun-Hee Choi, Lajmi Lakhal-Chaieb, Agnieszka Kröl, Bing Yu, Daniel Buchanan, Dennis Ahnen, Loic Le Marchand, Polly A Newcomb, Aung Ko Win, Mark Jenkins, Noralane M Lindor, Laurent Briollais
Background: The risk of cancers is well characterized in Lynch syndrome (LS) families but has been less studied in familial colorectal cancer type X (FCCTX) families. Methods: In this article, we compare the risk estimates of first and second colorectal cancers (CRCs) in 168 FCTTX and 780 LS families recruited through the Colon Cancer Family Registry as well as the risk of cancer-related deaths and disease-free survival (DFS) after a first CRC. Our methodology is based on a survival analysis approach, developed specifically to model the occurrence of successive cancers (ie, first and second CRCs) in the presence of competing risk events (ie, death from any causes)...
October 30, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30380081/re-risk-of-prostate-cancer-in-men-treated-with-5%C3%AE-reductase-inhibitors-a-large-population-based-prospective-study
#6
Patrick C Walsh
No abstract text is available yet for this article.
October 30, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30380079/response-to-walsh
#7
Peter Ström, Anna Wallerstedt Lantz, Henrik Grönberg, Tobias Nordström, Martin Eklund
No abstract text is available yet for this article.
October 30, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30371813/gonadotropin-releasing-hormone-gnrh-agonists-for-fertility-preservation-is-poems-the-final-verse
#8
Bo Yu, Nancy E Davidson
No abstract text is available yet for this article.
October 27, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30371800/final-analysis-of-the-prevention-of-early-menopause-study-poems-swog-intergroup-s0230
#9
Halle C F Moore, Joseph M Unger, Kelly-Anne Phillips, Frances Boyle, Erika Hitre, Anna Moseley, David J Porter, Prudence A Francis, Lori J Goldstein, Henry L Gomez, Carlos S Vallejos, Ann H Partridge, Shaker R Dakhil, Agustin A Garcia, Julie R Gralow, Janine M Lombard, John F Forbes, Silvana Martino, William E Barlow, Carol J Fabian, Lori M Minasian, Frank L Meyskens, Richard D Gelber, Gabriel N Hortobagyi, Kathy S Albain
Premature menopause is a serious long-term side effect of chemotherapy. We evaluated long-term pregnancy and disease-related outcomes for patients in S0230/POEMS, a study in premenopausal women with stage I-IIIA estrogen receptor-negative, progesterone receptor-negative breast cancer to be treated with cyclophosphamide-containing chemotherapy. Women were randomly assigned to standard chemotherapy with or without goserelin, a gonadotropin-releasing hormone agonist, and were stratified by age and chemotherapy regimen...
October 27, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30365005/effect-sizes-of-somatic-mutations-in-cancer
#10
Vincent L Cannataro, Stephen G Gaffney, Jeffrey P Townsend
A major goal of cancer biology is determination of the relative importance of the genetic alterations that confer selective advantage to cancer cells. Tumor sequence surveys have frequently ranked the importance of substitutions to cancer growth by P value or a false-discovery conversion thereof. However, P values are thresholds for belief, not metrics of effect. Their frequent misuse as metrics of effect has often been vociferously decried, even in cases when the only attributable mistake was omission of effect sizes...
October 26, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30346555/making-sure-we-don-t-forget-the-basics-when-using-machine-learning
#11
Aaron N Winn, Joan M Neuner
No abstract text is available yet for this article.
October 21, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30346554/automated-survival-prediction-in-metastatic-cancer-patients-using-high-dimensional-electronic-medical-record-data
#12
Michael F Gensheimer, A Solomon Henry, Douglas J Wood, Trevor J Hastie, Sonya Aggarwal, Sara A Dudley, Pooja Pradhan, Imon Banerjee, Eunpi Cho, Kavitha Ramchandran, Erqi Pollom, Albert C Koong, Daniel L Rubin, Daniel T Chang
Background: Oncologists use patients' life expectancy to guide decisions and may benefit from a tool that accurately predicts prognosis. Existing prognostic models generally use only a few predictor variables. We used an electronic medical record dataset to train a prognostic model for patients with metastatic cancer. Methods: The model was trained and tested using 12 588 patients treated for metastatic cancer in the Stanford Health Care system from 2008 to 2017...
October 21, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30346557/cancer-survivorship-and-employment-intersection-of-oral-agents-changing-workforce-dynamics-and-employers-perspectives
#13
Cathy J Bradley, Kelsey L Brown, Michelle Haan, Russell E Glasgow, Lee S Newman, Borsika Rabin, Debra P Ritzwoller, Liliana Tenney
The ability to continue employment during and following cancer diagnosis and treatment is critical to working-age cancer survivors. Prolonged survival combined with concerns of the financial burden associated with high-cost therapies makes the mitigation of work-related consequences all the more relevant, particularly in light of recent workforce trends and evolving employment dynamics. Research that integrates the needs of survivors, employers, and the workforce is required so that advancements are made to support employed cancer survivors...
October 19, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30329078/corrigendum
#14
(no author information available yet)
No abstract text is available yet for this article.
October 17, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30329076/expanding-the-evidence-base-in-geriatric-oncology-action-items-from-an-fda-asco-workshop
#15
Laura A Levit, Harpreet Singh, Heidi D Klepin, Arti Hurria
As part of the ongoing efforts to address the lack of clinical research on older adults with cancer, the American Society of Clinical Oncology (ASCO) and the US Food and Drug Administration cosponsored a public workshop on geriatric oncology in November 2017. The goals were to review progress, build collaborations across stakeholders, and generate new action items for increasing the evidence base for treating older adults with cancer. It built on previous work of the Institute of Medicine, ASCO, and the U13 Conferences convened by the Cancer and Aging Research Group, the National Cancer Institute, and the National Institute of Aging between 2010 and 2015...
October 17, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30329127/metformin-use-and-gastric-cancer-risk-in-diabetic-patients-after-helicobacter-pylori-eradication
#16
Ka Shing Cheung, Esther W Chan, Angel Y S Wong, Lijia Chen, Wai Kay Seto, Ian C K Wong, Wai K Leung
Background: Although prior studies showed metformin could reduce gastric cancer (GC) risk in patients with diabetes mellitus, they failed to adjust for Helicobacter pylori infection and glycemic control. We aimed to investigate whether metformin reduced GC risk in H. pylori-eradicated diabetic patients and its association with glycemic control. Methods: This was a territory-wide cohort study using hospital registry database, recruiting all diabetic patients who were prescribed clarithromycin-based triple therapy for H...
October 16, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30321398/a-reappraisal-of-sex-specific-cancer-survival-trends-among-adolescents-and-young-adults-in-the-united-states
#17
Lihua Liu, Diana J Moke, Kai-Ya Tsai, Amie Hwang, David R Freyer, Ann S Hamilton, Juanjuan Zhang, Myles Cockburn, Dennis Deapen
Background: Cancer survival among adolescents and young adults (AYAs) was previously reported as showing little or no improvement compared to younger or older counterparts. The role of the HIV/AIDS epidemic in the AYA survival deficit has not been evaluated. Methods: Using cancer registry data from the Surveillance, Epidemiology, and End Results program (SEER 9), we examined sex-specific 5-year relative survival trends for children (0-14 years old), AYAs (15-39 years old), and older adults (40 years and older) diagnosed with cancer during 1973-2009 and followed through the end of 2014...
October 15, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30321406/the-immune-landscape-of-prostate-cancer-and-nomination-of-pd-l2-as-a-potential-therapeutic-target
#18
Shuang G Zhao, Jonathan Lehrer, S Laura Chang, Rajdeep Das, Nicholas Erho, Yang Liu, Martin Sjöström, Robert B Den, Stephen J Freedland, Eric A Klein, R Jeffrey Karnes, Edward M Schaeffer, Melody Xu, Corey Speers, Paul L Nguyen, Ashley E Ross, June M Chan, Matthew R Cooperberg, Peter R Carroll, Elai Davicioni, Lawrence Fong, Daniel E Spratt, Felix Y Feng
Background: Immunotherapy has been less successful in treating prostate cancer than other solid tumors. We sought to better understand the immune landscape in prostate cancer and identify immune-related biomarkers and potential therapeutic targets. Methods: We analyzed gene expression data from 7826 prospectively collected prostatectomy samples (2013-2016), and 1567 retrospective samples with long-term clinical outcomes, for a total of 9393 samples, all profiled on the same commercial clinical platform in a CLIA-certified lab...
October 13, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30321404/finding-an-immunologic-beachhead-in-the-prostate-cancer-microenvironment
#19
Ravi A Madan, James L Gulley
No abstract text is available yet for this article.
October 13, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/30312457/height-and-body-mass-index-as-modifiers-of-breast-cancer-risk-in-brca1-2-mutation-carriers-a-mendelian-randomization-study
#20
Frank Qian, Shengfeng Wang, Jonathan Mitchell, Lesley McGuffog, Daniel Barrowdale, Goska Leslie, Jan C Oosterwijk, Wendy K Chung, D Gareth Evans, Christoph Engel, Karin Kast, Cora M Aalfs, Muriel A Adank, Julian Adlard, Bjarni A Agnarsson, Kristiina Aittomäki, Elisa Alducci, Irene L Andrulis, Banu K Arun, Margreet G E M Ausems, Jacopo Azzollini, Emmanuelle Barouk-Simonet, Julian Barwell, Muriel Belotti, Javier Benitez, Andreas Berger, Ake Borg, Angela R Bradbury, Joan Brunet, Saundra S Buys, Trinidad Caldes, Maria A Caligo, Ian Campbell, Sandrine M Caputo, Jocelyne Chiquette, Kathleen B M Claes, J Margriet Collée, Fergus J Couch, Isabelle Coupier, Mary B Daly, Rosemarie Davidson, Orland Diez, Susan M Domchek, Alan Donaldson, Cecilia M Dorfling, Ros Eeles, Lidia Feliubadaló, Lenka Foretova, Jeffrey Fowler, Eitan Friedman, Debra Frost, Patricia A Ganz, Judy Garber, Vanesa Garcia-Barberan, Gord Glendon, Andrew K Godwin, Encarna B Gómez Garcia, Jacek Gronwald, Eric Hahnen, Ute Hamann, Alex Henderson, Carolyn B Hendricks, John L Hopper, Peter J Hulick, Evgeny N Imyanitov, Claudine Isaacs, Louise Izatt, Ángel Izquierdo, Anna Jakubowska, Katarzyna Kaczmarek, Eunyoung Kang, Beth Y Karlan, Carolien M Kets, Sung-Won Kim, Zisun Kim, Ava Kwong, Yael Laitman, Christine Lasset, Min Hyuk Lee, Jong Won Lee, Jihyoun Lee, Jenny Lester, Fabienne Lesueur, Jennifer T Loud, Jan Lubinski, Noura Mebirouk, Hanne E J Meijers-Heijboer, Alfons Meindl, Austin Miller, Marco Montagna, Thea M Mooij, Patrick J Morrison, Emmanuelle Mouret-Fourme, Katherine L Nathanson, Susan L Neuhausen, Heli Nevanlinna, Dieter Niederacher, Finn C Nielsen, Robert L Nussbaum, Kenneth Offit, Edith Olah, Kai-Ren Ong, Laura Ottini, Sue K Park, Paolo Peterlongo, Georg Pfeiler, Catherine M Phelan, Bruce Poppe, Nisha Pradhan, Paolo Radice, Susan J Ramus, Johanna Rantala, Mark Robson, Gustavo C Rodriguez, Rita K Schmutzler, Christina G Hutten Selkirk, Payal D Shah, Jacques Simard, Christian F Singer, Johanna Sokolowska, Dominique Stoppa-Lyonnet, Christian Sutter, Yen Yen Tan, R Manuel Teixeira, Soo H Teo, Mary Beth Terry, Mads Thomassen, Marc Tischkowitz, Amanda E Toland, Katherine M Tucker, Nadine Tung, Christi J van Asperen, Klaartje van Engelen, Elizabeth J van Rensburg, Shan Wang-Gohrke, Barbara Wappenschmidt, Jeffrey N Weitzel, Drakoulis Yannoukakos, Mark H Greene, Matti A Rookus, Douglas F Easton, Georgia Chenevix-Trench, Antonis C Antoniou, David E Goldgar, Olufunmilayo I Olopade, Timothy R Rebbeck, Dezheng Huo
Background: BRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers remains unclear. Methods: We used Mendelian randomization approaches to evaluate the association of height and BMI on breast cancer risk, using data from the Consortium of Investigators of Modifiers of BRCA1/2 with 14 676 BRCA1 and 7912 BRCA2 mutation carriers, including 11 451 cases of breast cancer...
October 12, 2018: Journal of the National Cancer Institute
journal
journal
20157
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"